Roche's Genentech Receives FDA Approval For Vabysmo Prefilled Syringe (PFS) To Treat Three Leading Causes Of Vision Loss
Roche's Genentech Receives FDA Approval For Vabysmo Prefilled Syringe (PFS) To Treat Three Leading Causes Of Vision Loss
羅氏旗下的吉納泰克公司獲得FDA批准，用於治療三種主要導致視力喪失的疾病的Vabysmo預填充注射器（PFS）
- Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness –
- Designed to simplify administration, Vabysmo PFS provides retina specialists a ready-to-use option –
- Vabysmo PFS will be available for people living with wet AMD, DME and RVO –
- Vabysmo PFS是第一個也是唯一一個使用FDA批准的雙特異性抗體治療可能導致失明的視網膜疾病的預填針筒 -
- 爲簡化使用而設計，Vabysmo PFS爲視網膜專家提供了一個即用型選項 -
- Vabysmo PFS將爲患有溼性年齡相關性黃斑變性，糖尿病性黃斑水腫和視網膜靜脈阻塞的人提供服務 -